Montelukast Krka

Montelukast, the active ingredient in Montelukast Krka, is a leukotriene receptor antagonist presented as an oral tablet for systemic use and is approved in the European Union for respiratory disorders. It is employed to manage asthma, allergic rhinitis, and exercise‑induced bronchoconstriction in both adult and pediatric patients.

GNH USA supplies Montelukast Krka as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Montelukast acts on the leukotriene pathway to control airway inflammation and bronchoconstriction.

- Asthma: reduces frequency of wheezing episodes and improves lung function. - Allergic rhinitis: alleviates nasal congestion, sneezing and itching. - Exercise‑induced bronchoconstriction: prevents airway narrowing triggered by physical activity.

Montelukast may cause a range of adverse reactions that vary in frequency.

Common Side Effects: - Headache - Abdominal pain - Cough - Nausea - Sore throat - Dizziness

Serious or Rare Side Effects: - Allergic reactions such as rash, angioedema, or anaphylaxis - Neuropsychiatric events including agitation, depression, or suicidal thoughts - Elevated liver enzymes or hepatitis - Severe skin reactions like Stevens‑Johnson syndrome - Eosinophilic pneumonia - Anaphylactic shock

Before prescribing Montelukast, clinicians should consider several safety aspects.

- Assess asthma control before initiating: ensure patient is on appropriate inhaled therapy. - Monitor for neuropsychiatric symptoms: report mood changes promptly. - Use with caution in patients with hepatic impairment: adjust if needed. - Avoid in patients with known hypersensitivity to montelukast or excipients. - Review concomitant medications for potential interactions. - Store at room temperature: keep in the original container, protect from moisture and light.

Montelukast can interact with other medicines, requiring attention to avoid reduced efficacy or increased toxicity.

Major Interactions (Avoid): - Phenobarbital: may lower montelukast plasma concentrations. - Rifampin: induces metabolism, decreasing therapeutic effect. - Ketoconazole: can raise montelukast levels, increasing risk of adverse events.

Moderate Interactions (Monitor Closely): - Warfarin: potential alteration of anticoagulant effect. - Beta‑agonists: additive bronchodilation may occur. - Ciprofloxacin: may affect montelukast metabolism.